Mednet Logo
HomeDermatology
Dermatology

Dermatology

Clinical insights on skin conditions, dermatologic procedures, and treatment approaches from practicing dermatologists.

Recent Discussions

What is your approach to treatment of skin-limited cryoglobulinemic vasculitis in patients with Sjogren's syndrome who lack evidence of neurological or renal involvement?

3
1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Chicago

I have given this patient Rituximab prior with success.

Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?

1
3 Answers

Mednet Member
Mednet Member
Medical Oncology · Rogel Cancer Center/University of Michigan

Very good question. Data from use of neoadjuvant therapy in many solid tumors has shown that when they clinically regress, actual pathologic response is more heterogeneous. Although an area can appear to have a complete clinical response- random biopsies can show areas of viable microscopic tumor st...

Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?

4 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Florida

No

How do you utilize PRAME for melanocytic biopsies?

1
1 Answers

Mednet Member
Mednet Member
Dermatology · Eastern Virginia Medical School

PRAME is useful as one piece of information to help me decide if I have enough criteria for melanoma in situ. Like most IHC stains it is just a piece of the puzzle to me. In my experience, positivity of MIS is about 7-8/10, so I do not require PRAME positive to diagnose MIS. But positive PRAME helps...

When do you prescribe topical JAK inhibitors for adult patients with atopic dermatitis?

1 Answers

Mednet Member
Mednet Member
Dermatology · Stanford University School of Medicine

For adult patients with atopic dermatitis, I typically start with topical steroids with or without topical calcineurin inhibitors as maintenance therapy. If minimal improvement with topical steroids/calcineurin inhibitors, then I turn to other topicals including topical JAK inhibitors and/or crisabo...

What are your top takeaways from AAD 2023?

3
1 Answers

Mednet Member
Mednet Member
Dermatology · Weill Cornell Medical College

Top 3 takeaways: Confirmatory testing for onychomycosis is our responsibility as dermatologists and is cost-effective. Options for mycologic confirmation include KOH with microscopy, fungal culture, PCR, and histopathology. Terbinafine failures for onychomycosis may be due to non-compliance with tr...

Is close observation a reasonable option for elderly patients with a small basal cell carcinoma of the face?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Florida

Yes, depending on life expectancy, logistics, and morbidity of treatment which would be minimal with RT.

What oral therapies do you most commonly recommend for skin cancer prevention?

1 Answers

Mednet Member
Mednet Member
Dermatology · Princeton Dermatology Associates

I don't use a lot of oral medications for this problem. The one I use most is Nicotinamide and I think the data is really only supported for SCCs, not BCC. In the past, I have used low-dose oral retinoids but this can be challenging depending on co-morbid conditions and lesions tended to spring up w...

How do you manage pityriasis lichenoides chronica (PLC)?

1 Answers

Mednet Member
Mednet Member
Dermatology · Duke Health

If you are confident in the diagnosis of PLC, which isn't always easy to be, then no systemic workup is needed. The issue is the spectrum of disease and feeling confident you are truly dealing with PLC and not a related disorder with a possible risk of progression (LyP et al). Given that oftentimes ...

What is your approach to the use of intravenous sodium thiosulfate for the management of calciphylaxis in a patient with end stage kidney disease and on hemodialysis?

1 Answers

Mednet Member
Mednet Member
Nephrology · Medical College of Wisconsin

We have sodium thiosulfate 25gm IV each dialysis given during the last hour of treatment as a standard order in our dialysis order set. We have seen a useful response in some patients after several weeks, but there are no clear trial-based data to support the use of this treatment. I would certainly...